+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Disease Treatments Market- Product Image
Liver Disease Treatments Market- Product Image
New

Liver Disease Treatments Market

  • PDF Icon

    Report

  • 164 Pages
  • April 2025
  • Region: Global
  • BCC Research
  • ID: 6072188
Description Jump to:

The global market for liver disease treatments is estimated to increase from $46 billion in 2024 to reach $69.1 billion by 2030, at a compound annual growth rate (CAGR) of 7.1% from 2025 through 2030.

Liver diseases, which include cirrhosis, viral hepatitis and liver cancer, are responsible for more than 2 million deaths annually worldwide, or about 4% of all deaths (Devarbhavi H; et al.; Journal of Hepatology; 2023). An estimated 1 million people die each year from chronic liver disease and the cirrhosis it causes, and 600,000 to 900,000 die from liver cancer. Liver disease is the 11th most common cause of death worldwide, and the 15th most common cause of life years with a disability.

Leading pharmaceutical companies in the liver disease treatment market include:

  • Gilead Sciences: Known for its portfolio of hepatitis C treatments (e.g., Sovaldi, Harvoni) andongoing work in non-alcoholic steatohepatitis (NASH) treatments.
  • Bristol Myers Squibb: Active in the hepatitis market and liver cancer treatments with drugs like Opdivo and Yervoy.
  • AbbVie: Its hepatitis C treatment, Mavyret, is one of the leading drugs on the market.
  • Merck & Co.: Developing immunotherapies for liver cancer and also involved in hepatitis B treatments.

Biotechnology firms developing novel therapies for liver disorders, particularly those like liver fibrosis and NASH, are also showing interest in the market.

Report Scope

This report on the global market for liver disease treatments provides qualitative and quantitative data on the current market dynamics. It discusses different liver diseases and their treatment modalities.

Analyses of the most frequently used products, clinical trials, new product approvals, and emerging technologies are also included. The demographics of the major regions - North America, Europe, Asia-Pacific, South America, and the Middle East and Africa - as well as their prospects for growth are summarized. The profiles of leading companies in the market and their strategies are also discussed.

The market for liver disease treatments is broken into hepatitis, non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma, autoimmune liver diseases, alcohol-induced liver disease (ALD), chronic liver disease, and others. The growth potential and forecast data are discussed for each disease for the aforementioned regions and many countries.

The report includes global revenue in $ millions for the base year of 2024, estimates for 2025, and data for the forecast period of 2026 through 2030.

The report includes:

  • 52 data tables and 63 additional tables
  • Analyses of the trends in the global markets for liver disease treatments, with revenue data from 2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029
  • Estimates of the size and revenue prospects for the global market, along with a market share analysis by product (drug) type, disease type, route of administration, end user, and region
  • Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
  • Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses
  • An assessment of the major drugs that can cause liver disease, the market’s current situation and future prospects, clinical trials, new developments, and pipeline products
  • An analysis of the key patent grants and recently published patents
  • Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
  • Analysis of the industry structure, including companies’ product offerings, strategic alliances, M&A activity, venture fundings and investment outlook
  • Company profiles of major players within the industry, including Gilead Sciences Inc., Bristol Myers Squibb Co., AbbVie Inc., and Merck & Co. Inc.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Overview
  • Classification of Therapies, by Disease and Product
  • Hepatitis
  • Liver Tumors and Liver Cancer
  • Autoimmune Liver Diseases
  • Alcohol-induced liver disease
  • Chronic Liver Disease
  • Non-Alcoholic Fatty Liver Disease
  • Analysis of Macroeconomic Factors
  • Population Demographics and Aging Population
  • Global Economic Growth
  • Geopolitical Risks, Trade Wars, and Supply Chain Disruptions
  • Public Awareness and Education
  • Porter’s Five Forces
  • Potential for New Entrants (Moderate to Low)
  • Bargaining Power of Suppliers (Moderate to High)
  • Bargaining Power of Buyers (Moderate to High)
  • Threat of Substitute Products or Services (Low to Moderate)
  • Industry Competitiveness (High)
Chapter 3 Market Dynamics
  • Overview
  • Market Drivers
  • Increasing Incidence of Liver Diseases
  • Consumption of Alcohol and Improper Diet
  • Government Initiatives to Provide Vaccines and Grow Awareness
  • Market Restraints
  • FDA Approvals and Stringent Government Regulations
  • Side Effects and Risks Associated with Drugs
  • Market Opportunities
  • Advances in Treatment Options
  • Emerging Markets and Access to Treatment
Chapter 4 Regulatory Landscape
  • Global Regulatory Agencies
  • U.S. Food and Drug Administration
  • European Medicines Agency
  • Japan’s Pharmaceuticals and Medical Devices Agency
  • China’s National Medical Products Administration
  • Considerations in Liver Drug Development
Chapter 5 Emerging Trends and Pipeline Analysis
  • Emerging Trends
  • Personalized Medicine in Liver Disease
  • Advances in Liver Transplantation
  • Regenerative Medicine and Stem Cell Therapy
  • Immunotherapy for Liver Cancer
  • Repairing Liver Disease with mRNA
  • Pipeline Analysis
  • Patent Analysis
  • Findings
Chapter 6 Market Segmentation Analysis
  • Segmentation Breakdown
  • Market Breakdown, by Disease Type
  • Takeaways
  • Hepatitis
  • Non-Alcoholic Fatty Liver Disease
  • Hepatocellular Carcinoma
  • Autoimmune Liver Diseases
  • Alcohol-induced Liver Disease (ALD)
  • Chronic Liver Disease
  • Other Liver-Related Diseases
  • Geographic Breakdown
  • Market Breakdown, by Region
  • Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa
Chapter 7 Competitive Intelligence
  • Takeaways
  • Market Ranking of Leading Companies
  • Strategic Analysis
  • Venture Funding and Investments
Chapter 8 Sustainability in the Liver Disease Treatment Industry: ESG Perspective
  • Overview
  • Environmental Sustainability
  • Social Responsibility (S)
  • Governance
  • ESG Risk Ratings
  • Concluding Remarks
Chapter 9 Appendix
  • Research Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • ABBVIE INC.
  • ASTRAZENECA
  • BAYER AG
  • BIOTEST AG
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • GILEAD SCIENCES INC.
  • GSK PLC.
  • INTERCEPT PHARMACEUTICALS INC.
  • MADRIGAL PHARMACEUTICALS
  • MERCK & CO. INC.
  • NOVARTIS AG
  • SALIX PHARMACEUTICALS
  • SANOFI
  • TAKEDA PHARMACEUTICAL CO. LTD.
  • Emerging Start-ups/Market Disruptors
List of Tables
Summary Table: Global Market for Liver Disease Treatments, by Region, Through 2030
Table 1: Vaccines for Preventing Hepatitis A and B
Table 2: Drugs Used to Treat Autoimmune Liver Diseases
Table 3: Porter’s Five Forces: Rating Scale
Table 4: Estimates of the Burden of Chronic Hepatitis B and C, by WHO Region, 2022
Table 5: Possible Side Effects of Liver Treatment Drugs
Table 6: FDA Drug Approvals for Liver Treatment, 2022-2024
Table 7: EMA Drug Approvals for Liver Treatment, 2024 and 2025
Table 8: Drugs Approved by the PMDA for Liver Treatment, 2022-2024
Table 9: Pipeline Drugs for Liver Disease Treatment in Phases 3 and 4, 2024
Table 10: Granted Patents in Liver Drugs, 2023-2025
Table 11: Global Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 12: Global Market for Treatments for Hepatitis, by Region, Through 2030
Table 13: Pipeline Drugs for NAFLD
Table 14: Global Market for Treating NAFLD, by Region, Through 2030
Table 15: Countries with Highest Incidence of Liver Cancer, 2022
Table 16: Global Market for Treating Hepatocellular Carcinoma, by Region, Through 2030
Table 17: Global Market for Treating Autoimmune Liver Diseases, by Region, Through 2030
Table 18: Global Market for Treating Alcohol-induced Liver Disease, by Region, Through 2030
Table 19: Global Market for Treating Chronic Liver Disease, by Region, Through 2030
Table 20: Global Market for Treating Other Liver Diseases, by Region, Through 2030
Table 21: Global Market for Liver Disease Treatments, by Region, Through 2030
Table 22: North American Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 23: North American Market for Liver Disease Treatments, by Country, Through 2030
Table 24: U.S. Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 25: Canadian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 26: Liver Transplants from Donors, Per Center in Mexico, in 2023
Table 27: Mexican Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 28: European Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 29: European Market for Liver Disease Treatments, by Country, Through 2030
Table 30: German Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 31: Premature Mortality Due to Alcoholic Liver Disease, 2019, 2022, 2023
Table 32: U.K. Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 33: French Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 34: Spanish Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 35: Italian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 36: Rest of European Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 37: Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 38: Asia-Pacific Market for Liver Disease Treatments, by Country, Through 2030
Table 39: Chinese Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 40: Japanese Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 41: Indian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 42: Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 43: South American Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 44: South American Market for Liver Disease Treatments, by Country, Through 2030
Table 45: Brazilian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 46: Argentinian Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 47: Rest of South American Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 48: MEA Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 49: MEA Market for Liver Disease Treatments, by Region, Through 2030
Table 50: Middle East Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 51: African Market for Liver Disease Treatments, by Disease Type, Through 2030
Table 52: Leading Companies in the Market for Liver Disease Treatments, 2024
Table 53: Recent Venture Funding in the Liver Disease Treatment Industry
Table 54: ESG Risk Rankings for Pharmaceutical Firms in the Liver Disease Market
Table 55: Report Information Sources
Table 56: Abbreviations Used in the Report
Table 57: AbbVie Inc.: Company Snapshot
Table 58: AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 59: AbbVie Inc.: Product Portfolio
Table 60: AstraZeneca: Company Snapshot
Table 61: AstraZeneca: Financial Performance, FY 2023 and 2024
Table 62: AstraZeneca: Product Portfolio
Table 63: AstraZeneca: News/Key Developments, 2022 and 2023
Table 64: Bayer AG: Company Snapshot
Table 65: Bayer AG: Financial Performance, FY 2023 and 2024
Table 66: Bayer AG: Product Portfolio
Table 67: Bayer AG: News/Key Developments, 2023 and 2024
Table 68: Biotest AG: Company Snapshot
Table 69: Biotest AG: Financial Performance, FY 2023 and 2024
Table 70: Biotest AG: Product Portfolio
Table 71: Biotest AG: News/Key Developments, 2023
Table 72: Bristol-Myers Squibb Co.: Company Snapshot
Table 73: Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 74: Bristol-Myers Squibb Co.: Product Portfolio
Table 75: Bristol-Myers Squibb Co.: News/Key Developments, 2025
Table 76: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 77: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 78: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 79: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 80: Gilead Sciences Inc.: Company Snapshot
Table 81: Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 82: Gilead Sciences Inc.: Product Portfolio
Table 83: Gilead Sciences Inc.: News/Key Developments, 2024
Table 84: GSK plc.: Company Snapshot
Table 85: GSK plc.: Financial Performance, FY 2023 and 2024
Table 86: GSK plc.: Product Portfolio
Table 87: GSK plc.: News/Key Developments, 2024
Table 88: Intercept Pharmaceuticals Inc.: Company Snapshot
Table 89: Intercept Pharmaceuticals Inc.: Product Portfolio
Table 90: Intercept Pharmaceuticals Inc.: News/Key Developments, 2024
Table 91: Madrigal Pharmaceuticals: Company Snapshot
Table 92: Madrigal Pharmaceuticals: Financial Performance, FY 2023 and 2024
Table 93: Madrigal Pharmaceuticals: Product Portfolio
Table 94: Madrigal Pharmaceuticals: News/Key Developments, 2024
Table 95: Merck & Co. Inc.: Company Snapshot
Table 96: Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 97: Merck & Co. Inc.: Product Portfolio
Table 98: Merck & Co. Inc.: News/Key Developments, 2024
Table 99: Novartis AG: Company Snapshot
Table 100: Novartis AG: Financial Performance, FY 2023 and 2024
Table 101: Novartis AG: Product Portfolio
Table 102: Novartis AG: News/Key Developments, 2022
Table 103: Salix Pharmaceuticals: Company Snapshot
Table 104: Salix Pharmaceuticals: Product Portfolio
Table 105: Salix Pharmaceuticals: News/Key Developments, 2023
Table 106: Sanofi: Company Snapshot
Table 107: Sanofi: Financial Performance, FY 2023 and 2024
Table 108: Sanofi: Product Portfolio
Table 109: Sanofi: News/Key Developments, 2024
Table 110: Takeda Pharmaceutical Co. Ltd.: Company Snapshot
Table 111: Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 112: Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 113: Takeda Pharmaceutical Co. Ltd.: News/Key Developments, 2023 and 2024
Table 114: Emerging Startups
List of Figures
Summary Figure: Shares of Global Market for Liver Disease Treatments, by Region, 2024
Figure 1: Porter’s Five Forces Analysis
Figure 2: Market Dynamics of Liver Disease Treatments
Figure 3: Distribution of Death by Liver Diseases in England, by Age Group, 2020
Figure 4: Clinical Trial Studies of Liver Treatment Drugs, by Trial Phase, 2024
Figure 5: Patent Analysis of Liver Treatment Drugs, 2022-2025
Figure 6: Shares of Global Market for Liver Disease Treatments, by Disease Type, 2024
Figure 7: Shares of Global Market for Hepatitis Treatments, by Region, 2024
Figure 8: Shares of Global Market for Treating NAFLD, by Region, 2024
Figure 9: Shares of Global Market for Treating Hepatocellular Carcinoma, by Region, 2024
Figure 10: Shares of Global Market for Treating Autoimmune Liver Diseases, by Region, 2024
Figure 11: Shares of Global Market for Treating Alcohol-induced Liver Disease, by Region, 2024
Figure 12: Shares of Global Market for Treating Chronic Liver Disease, by Region, 2024
Figure 13: Shares of Global Market for Treating Other Liver Diseases, by Region, 2024
Figure 14: Shares of Global Market for Liver Disease Treatments, by Region, 2024
Figure 15: Shares of North American Market for Liver Disease Treatments, by Disease Type, 2024
Figure 16: Shares of North American Market for Liver Disease Treatments, by Country, 2024
Figure 17: Shares of U.S. Market for Liver Disease Treatments, by Disease Type, 2024
Figure 18: Shares of Canadian Market for Liver Diseases Treatments, by Disease Type, 2024
Figure 19: Shares of Mexican Market for Liver Disease Treatments, by Disease Type, 2024
Figure 20: Shares of European Market for Liver Disease Treatments, by Disease Type, 2024
Figure 21: Shares of European Market for Liver Disease Treatments, by Country, 2024
Figure 22: Deaths Due to Chronic Liver Disease in Germany, 2011-2021
Figure 23: Shares of German Market for Liver Disease Treatments, by Disease Type, 2024
Figure 24: Shares of U.K. Market for Liver Disease Treatments, by Disease Type, 2024
Figure 25: Shares of French Market for Liver Disease Treatments, by Disease Type, 2024
Figure 26: Shares of Spanish Market for Liver Disease Treatments, by Disease Type, 2024
Figure 27: Shares of Italian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 28: Shares of Rest of European Market for Liver Disease Treatments, by Disease Type, 2024
Figure 29: Shares of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024
Figure 30: Shares of Asia-Pacific Market for Liver Disease Treatments, by Country, 2024
Figure 31: Shares of Chinese Market for Liver Disease Treatments, by Disease Type, 2024
Figure 32: Shares of Japanese Market for Liver Disease Treatments, by Disease Type, 2024
Figure 33: Shares of Indian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 34: Shares of Rest of Asia-Pacific Market for Liver Disease Treatments, by Disease Type, 2024
Figure 35: Shares of South American Market for Liver Disease Treatments, by Disease Type, 2024
Figure 36: Shares of South American Market for Liver Disease Treatments, by Country, 2023
Figure 37: Shares of Brazilian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 38: Shares of Argentinian Market for Liver Disease Treatments, by Disease Type, 2024
Figure 39: Shares of Rest of South American Market for Liver Disease Treatments, by Disease Type, 2024
Figure 40: Shares of MEA Market for Liver Disease Treatments, by Disease Type, 2024
Figure 41: Shares of MEA Market for Liver Disease Treatments, by Region, 2024
Figure 42: Shares of Middle East Market for Liver Disease Treatments, by Disease Type, 2024
Figure 43: Shares of African Market for Liver Disease Treatments, by Disease Type, 2024
Figure 44: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 45: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 46: AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 47: AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 48: Bayer AG: Revenue Shares, by Business Unit, FY 2024
Figure 49: Bayer AG: Revenue Shares, by Country/Region, FY 2024
Figure 50: Biotest AG: Revenue Shares, by Business Unit, FY 2024
Figure 51: Biotest AG: Revenue Shares, by Country/Region, FY 2024
Figure 52: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 53: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 54: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 55: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 56: Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 57: Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 58: GSK plc.: Revenue Shares, by Business Unit, FY 2024
Figure 59: GSK plc.: Revenue Shares, by Country/Region, FY 2024
Figure 60: Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 61: Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 62: Novartis AG: Revenue Shares, by Business Unit, FY 2024
Figure 63: Novartis AG: Revenue Shares, by Country/Region, FY 2024
Figure 64: Sanofi: Revenue Shares, by Business Unit, FY 2024
Figure 65: Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 66: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 67: Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2023

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca
  • Bayer AG
  • Biotest AG
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GSK PLC
  • Intercept Pharmaceuticals Inc.
  • Madrigal Pharmaceuticals
  • Merck & Co. Inc.
  • Novartis AG
  • Salix Pharmaceuticals
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

Table Information

Report AttributeDetails
No. of Pages164
PublishedApril 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 46 Billion
Forecasted Market Value ( USD ) by 2030 $ 69.1 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Liver Diseases Therapeutics Market Report 2025 - Product Image

Liver Diseases Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Liver Disease Therapeutic Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Liver Disease Therapeutic Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Chronic Liver Diseases Therapeutics Global Market Report 2025 - Product Image

Chronic Liver Diseases Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Liver Disease Treatment Market Report by Treatment Type, Disease Type, End User, and Region 2024-2032 - Product Image

Liver Disease Treatment Market Report by Treatment Type, Disease Type, End User, and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.